Credit: K KStock/Adobe stock
The availability of GLP-1 drugs for weight loss as well as diabetes is driving a historic shift in traditional drug spending increases, outpacing specialty drug trends for the first time.
In 2024, drugs targeting weight management accounted for about half of the total increase in drug spend and equaled 6.7% of total drug costs, according to Pharmacy in Focus: Navigating the GLP-1 Conundrum, a new report from Evernorth Research Institute. GLP-1 therapies are poised for continued growth, with nearly one-quarter of consumers currently considering them.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Alan Goforth
Alan Goforth is a freelance writer in suburban Kansas City. In addition to freelancing for several publications, he has written a dozen books about sports and other topics.
